| Pharmaceutical Information |
| Drug Name |
Ixekizumab |
| Drug ID |
BADD_D01224 |
| Description |
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.
Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| Indications and Usage |
Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| Marketing Status |
Prescription |
| ATC Code |
L04AC13 |
| DrugBank ID |
DB11569
|
| KEGG ID |
D10071
|
| MeSH ID |
C549079
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D08NMV
|
| NDC Product Code |
63419-0536; 0002-7724; 0002-1445 |
| Synonyms |
ixekizumab | Taltz | LY2439821 | LY-2439821 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1143503-69-8 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
